Medical management of claudication

Area of Science:

• Vascular Medicine
• Cardiovascular Disease Management
• Public Health

Background:

• Peripheral artery disease (PAD) is a prevalent condition linked to substantial patient morbidity and mortality.
• Effective management of PAD is crucial for all patients, regardless of revascularization decisions.
• Key objectives in PAD management include mitigating cardiovascular risks and enhancing patient quality of life.

Purpose of the Study:

• To outline the essential components of optimal medical management for peripheral artery disease (PAD).
• To emphasize the importance of individualized risk factor modification and lifestyle interventions.
• To provide guidance on pharmacologic and non-pharmacologic therapies for PAD patients.

Main Methods:

• Comprehensive risk factor assessment and aggressive modification.
• Individualized treatment plans incorporating lifestyle changes and pharmacotherapy.
• Emphasis on smoking cessation, antiplatelet therapy, statin use, and ACE inhibitors.
• Integration of supervised exercise programs for symptom improvement.

Main Results:

• Aggressive risk factor modification significantly reduces cardiovascular morbidity and mortality in PAD patients.
• Exercise therapy is highly effective in improving claudication symptoms and functional capacity.
• Pharmacologic interventions, including antiplatelet agents and statins, are cornerstones of PAD management.
• Cilostazol offers symptomatic benefit for select patients with claudication.

Conclusions:

• Optimal medical management is paramount for all patients with peripheral artery disease (PAD).
• A multi-faceted approach combining risk factor control, pharmacotherapy, and exercise is essential.
• Individualized treatment strategies are necessary to improve outcomes and quality of life in PAD.